Cargando…

Longitudinal biomarkers in amyotrophic lateral sclerosis

OBJECTIVE: To investigate neurodegenerative and inflammatory biomarkers in people with amyotrophic lateral sclerosis (PALS), evaluate their predictive value for ALS progression rates, and assess their utility as pharmacodynamic biomarkers for monitoring treatment effects. METHODS: De‐identified, lon...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Fen, Zhu, Yuda, Hsiao‐Nakamoto, Jennifer, Tang, Xinyan, Dugas, Jason C., Moscovitch‐Lopatin, Miriam, Glass, Jonathan D., Brown, Robert H., Ladha, Shafeeq S., Lacomis, David, Harris, Jeffrey M., Scearce‐Levie, Kimberly, Ho, Carole, Bowser, Robert, Berry, James D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7359115/ https://www.ncbi.nlm.nih.gov/pubmed/32515902 http://dx.doi.org/10.1002/acn3.51078

Ejemplares similares

Cystatin C: A Candidate Biomarker for Amyotrophic Lateral Sclerosis
por: Wilson, Meghan E., et al.
Publicado: (2010)

Evaluation of Amyotrophic Lateral Sclerosis-Induced Muscle Degeneration Using Magnetic Resonance-Based Relaxivity Contrast Imaging (RCI)
por: Ragunathan, Sudarshan, et al.
Publicado: (2021)

Immune Modulation in the Treatment of Amyotrophic Lateral Sclerosis: A Review of Clinical Trials
por: Khalid, Syed I., et al.
Publicado: (2017)

Neuronal mitochondrial dysfunction in sporadic amyotrophic lateral sclerosis is developmentally regulated
por: Singh, Tanisha, et al.
Publicado: (2021)

Measurement of cystatin C functional activity in the cerebrospinal fluid of amyotrophic lateral sclerosis and control subjects
por: Wilson, Meghan E, et al.
Publicado: (2013)

Characterization of Social Behaviors in caspase-3 deficient mice
por: Lo, Shih-Ching, et al.
Publicado: (2016)

A meta-analysis of post-exercise outcomes in people with amyotrophic lateral sclerosis
por: Donohue, Cara, et al.
Publicado: (2023)

Receptor for Advanced Glycation End Products and its Inflammatory Ligands are Upregulated in Amyotrophic Lateral Sclerosis
por: Juranek, Judyta K., et al.
Publicado: (2015)

Engineered G protein coupled receptors reveal independent regulation of internalization, desensitization and acute signaling
por: Scearce-Levie, Kimberly, et al.
Publicado: (2005)

Use of diffusion spectrum imaging in preliminary longitudinal evaluation of amyotrophic lateral sclerosis: development of an imaging biomarker
por: Abhinav, Kumar, et al.
Publicado: (2014)

Cross-sectional and longitudinal measures of chitinase proteins in amyotrophic lateral sclerosis and expression of CHI3L1 in activated astrocytes
por: Vu, Lucas, et al.
Publicado: (2020)

Predicting disease progression in amyotrophic lateral sclerosis
por: Taylor, Albert A., et al.
Publicado: (2016)

Radicava/Edaravone Findings in Biomarkers From Amyotrophic Lateral Sclerosis (REFINE-ALS): Protocol and Study Design
por: Berry, James, et al.
Publicado: (2021)

Addressing heterogeneity in amyotrophic lateral sclerosis CLINICAL TRIALS
por: Goyal, Namita A., et al.
Publicado: (2020)

COL25A1 triggers and promotes Alzheimer’s disease-like pathology in vivo
por: Tong, Ying, et al.
Publicado: (2009)

Safety, pharmacokinetics and target engagement of novel RIPK1 inhibitor SAR443060 (DNL747) for neurodegenerative disorders: Randomized, placebo‐controlled, double‐blind phase I/Ib studies in healthy subjects and patients
por: Vissers, Maurits F. J. M., et al.
Publicado: (2022)

The Peripheral Immune System and Amyotrophic Lateral Sclerosis
por: McCombe, Pamela A., et al.
Publicado: (2020)

Global alterations to the choroid plexus blood-CSF barrier in amyotrophic lateral sclerosis
por: Saul, J., et al.
Publicado: (2020)

IL6 receptor(358)Ala variant and trans-signaling are disease modifiers in amyotrophic lateral sclerosis
por: Wosiski-Kuhn, Marlena, et al.
Publicado: (2019)

Longitudinal comparison of the self‐entry Amyotrophic Lateral Sclerosis Functional Rating Scale‐Revised (ALSFRS‐RSE) and Rasch‐Built Overall Amyotrophic Lateral Sclerosis Disability Scale (ROADS) as outcome measures in people with amyotrophic lateral sclerosis
por: Johnson, Stephen A., et al.
Publicado: (2022)

Design and Initial Results of a Multi-Phase Randomized Trial of Ceftriaxone in Amyotrophic Lateral Sclerosis
por: Berry, James D., et al.
Publicado: (2013)

Fibroblast bioenergetics to classify amyotrophic lateral sclerosis patients
por: Konrad, Csaba, et al.
Publicado: (2017)

Artificial intelligence in neurodegenerative disease research: use of IBM Watson to identify additional RNA-binding proteins altered in amyotrophic lateral sclerosis
por: Bakkar, Nadine, et al.
Publicado: (2017)

The Heritability of Amyotrophic Lateral Sclerosis in a Clinically Ascertained United States Research Registry
por: Wingo, Thomas S., et al.
Publicado: (2011)

Amyotrophic lateral sclerosis
por: Wijesekera, Lokesh C, et al.
Publicado: (2009)

Repetitive Nerve Stimulation in Amyotrophic Lateral Sclerosis
por: Sun, Xiao-Sun, et al.
Publicado: (2018)

Rate of speech decline in individuals with amyotrophic lateral sclerosis
por: Eshghi, Marziye, et al.
Publicado: (2022)

Long‐term survival of participants in the CENTAUR trial of sodium phenylbutyrate‐taurursodiol in amyotrophic lateral sclerosis
por: Paganoni, Sabrina, et al.
Publicado: (2020)

Amyotrophic lateral sclerosis: improving care with a multidisciplinary approach
por: Hogden, Anne, et al.
Publicado: (2017)

Smads as muscle biomarkers in amyotrophic lateral sclerosis
por: Si, Ying, et al.
Publicado: (2014)

Human cerebral evolution and the clinical syndrome of amyotrophic lateral sclerosis
por: Henderson, Robert D, et al.
Publicado: (2019)

Redox Regulation in Amyotrophic Lateral Sclerosis
por: Parakh, Sonam, et al.
Publicado: (2013)

Mutations in the Matrin 3 gene cause familial amyotrophic lateral sclerosis
por: Johnson, Janel O., et al.
Publicado: (2014)

Behavior Matters—Cognitive Predictors of Survival in Amyotrophic Lateral Sclerosis
por: Hu, William T., et al.
Publicado: (2013)

Exposing asymmetric gray matter vulnerability in amyotrophic lateral sclerosis
por: Devine, Matthew S., et al.
Publicado: (2015)

Metabolic Reprogramming in Amyotrophic Lateral Sclerosis
por: Szelechowski, M., et al.
Publicado: (2018)

Genetic variability in sporadic amyotrophic lateral sclerosis
por: Van Daele, Sien Hilde, et al.
Publicado: (2023)

Gut microbiome differences between amyotrophic lateral sclerosis patients and spouse controls
por: HERTZBERG, VICKI S., et al.
Publicado: (2022)

Amyotrophic lateral sclerosis and neuroregeneration
Publicado: (2012)

Mimickers of Amyotrophic Lateral Sclerosis
por: Dubey, Ayush, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_o27i97jssv2aen6htfh85lhe6r